Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Palantir Technologies | Cerebras Systems | Eli Lilly and Company | |
|---|---|---|---|
| Moat rating | narrow The FY2025 10-K competition section concedes that some competitors have 'greater name recognition, longer operating histories, and larger customer bases', 'larger and more mature intellectual property portfolios', and 'substantially greater financial, technical, and other resources' — and that Palantir is 'fundamentally competing with the internal software development efforts of our potential customers'. A real moat exists but the filing's own disclosure caps it below wide. | narrow One-of-a-kind silicon sold to very few buyers: the IPO prospectus discloses G42 at 24.0% of 2025 revenue (85.0% in 2024), MBZUAI at 62.0% of 2025 revenue, and a December 2025 MRA with OpenAI representing 'a substantial portion of our projected revenues over the next several years' — against a competitive field the same document names as NVIDIA, AMD, Intel, hyperscaler accelerators and the major clouds. | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. |
| Moat type | switching costs The 10-K reports that 'our top three customers by revenue for the year ended December 31, 2025, have been with us for an average of ten years' and that a significant portion of revenue comes from existing customers expanding their relationships. The filing explicitly disclaims patent dependence — 'we are not dependent on any particular patent or application' — so the durable source is embedded deployment, not IP. | intangibles ip Wafer-scale integration is the moat's substance: the prospectus contrasts the WSE-3's 4 trillion transistors on 46,225 mm² of silicon with NVIDIA's B200 at 208 billion on roughly 1,600 mm² — a commercial chip category with one occupant. | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. |
| Leadership | at parity The 10-K claims only that 'we believe we generally compete favorably with our competitors', while conceding rivals' greater scale, recognition and resources. The filing does not assert market leadership, so a leader band is not groundable from it. | clear leader Scoped to the category the record supports: wafer-scale integration has no other commercial occupant per the prospectus's own comparison, and the Q2 release claims — attributed, via AMD and AWS partnerships — leadership in disaggregated inference, a technique the prospectus defines. | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. |
| Pricing power | strong FY2025 gross profit of $3.7 billion on a gross margin of 82% (84% excluding stock-based compensation), up from 80% (83% ex-SBC) in FY2024 — a sustained and rising 80%+ gross margin. | moderate The CFO states Q2 'significantly improved core gross and operating margins compared to a year ago' — improving, from a base where three named customers hold most of the revenue and the leverage that comes with it. | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. |
| Summary | Customers who deploy Foundry model their operations in the Ontology and build workflows on top of it, so displacement means rebuilding that layer rather than swapping a vendor — which is why the 10-K frames its main competitor as the customer's own internal build effort. Ten-year average tenure among the top three customers is the filing's own evidence that those deployments persist. | Cerebras bet that AI compute should be one enormous chip rather than many small ones — 'quantities of compute and memory never before assembled on a single commercial chip,' avoiding 'the latency and the power-draw induced by the traditional approach,' in the prospectus's words — and is converting that bet into an inference cloud: Q2 2026 cloud revenue grew 281% with 600 MW of data center capacity under contract and $25.4 billion of remaining performance obligations. The concentration that funded the bet is the risk that remains: two related-party Gulf customers were 86% of 2025 revenue between them, with the OpenAI MRA now layered on top. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." |
| Chain position | Application-layer software sitting above the cloud and model providers; AIP connects to third-party LLMs rather than supplying them. | Layer-4 wafer-scale accelerators plus an inference cloud — hardware vendor and specialized cloud in one node. | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.11 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.20 at weight 0.20 · swarm bearish Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. |